Menu ×

HEALTHCARE & PHARMACEUTICAL

West Syndrome Market Analysis by Product Type {Solid Dosage (Tablet and Capsule), and Liquid Dosage (Injectable and Others)}; by Administration Route (Parenteral, Oral, and Others); by Treatment (Anticonvulsant, Benzodiazepine, Corticosteroids, and Vitamin B); by Distribution Channel (Retail, Online, and Hospitals); and by End-User (Hospitals, Homecare, and Clinics) – Global Supply & Demand Analysis & Opportunity Outlook 2023-2033

  • Text Size:

Inflation And Looming Recession to Haunt Businesses:

In 2022 & 2023, market players expected to sail in rough waters; might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain. Further, U.S. economy is expected to grow merely by 3% in 2022.

Request Insights

Purchasing power in the couPurchasing power in the country is expected to fell nearly by 2.5%. On the other hand, European countries to see the worst coming in the form of energy crisis especially in upcoming winters!! Right after COVID-19, inflation has started gripping the economies across the globe. Higher than anticipated inflation, especially in western world had raised concerns for national banks and financial institutions to control the economic loss and safeguard the interest of the businesses. Increased interest rates, strong USD inflated oil prices, looming prices for gas and energy resources due to Ukraine-Russia conflict, China economic slowdown (~4% in 2022) disrupting the production and global supply chain and other factors would impact each industry negatively.                                                         Request Insights

Read More

IN THE NEWS

  • Eisai Co., Ltd. to announce its first presentation with Merck & Co., Inc. associated with the Phase 3 LEAP-002 trial investigating LENVIMA which is a receptor tyrosine, orally available and discovered by Eisai. Furthermore, the anti-PD-1 therapy, plus KEYTRUSA, from Merck & Co., Inc., is also introduced as a first-line treatment for uHCC.
  • SK Biopharmaceuticals Co., Ltd. to announce the result of the long-term randomized open-label extension (OLE). The company is focused on treatment development for central nervous system (CNS) disorders. Data analyzed in the OLE phase was taken from nearly 355 adult patients having focal seizures.

Global West Syndrome Market Size, Forecast, and Trend Highlights Over 2023 - 2033

Base Year

2022

Forecast Year

2023-2033

CAGR

~5%

The global west syndrome market is estimated to garner robust revenue by the end of 2033 by growing at a CAGR of ~5% over the forecast period, i.e., 2023 – 2033. Further, the market generated remarkable revenue in the year 2022. The growth of the market can primarily be attributed to the rising prevalence of epilepsy. World Health Organization (WHO) provided a report stating that nearly 5 million individuals are diagnosed with epilepsy every year.

West-Syndrome-Market-Size

Get more information on this report: Request Sample PDF

Global west syndrome market trends such as, growing awareness of west syndrome in the global population and rising healthcare expenditure are projected to influence the growth of the market positively over the forecast period. In a report published by the World Bank, it was stated that in 2019, the healthcare expenditure reached 1,121.9 per capita. West syndrome is a serious medical condition with a drastically irregular pattern of brain waves which is also known as hypsarrhythmia. West syndrome also includes features such as, infantile spasms and loss of developmental milestones. Moreover, spiking R&D spending on neurological illnesses and the rising inclination of the global population toward novel therapies are further anticipated to propel the growth of the market over the forecast period.

Global West Syndrome Market: Growth Drivers and Challenges

Growth Drivers

  • Growing Incidence of Traumatic Brain Injuries to Boost the Market Growth

As of 2019, around 200,000 people were noticed to be hospitalized while nearly 62,000 people died due to traumatic brain injuries in same year.

Traumatic brain injury, shortly known as TBI can affect the functionality of the brain in multiple ways. It is categorized into two categories that are closed and penetrating brain injury. TBI can also cause death and serious disabilities becoming the major causes of death in the United States. Hence, such a higher prevalence is estimated to hike the market growth over the forecast period.

  • Higher Prevalence of Drug Seizure

In 2022-21, about 5500 drug seizures per million inhabitants were observed solely in London.

  • Significant Growth in the Imaging Technology

For instance, the diagnostic imaging devices segment was valued at nearly USD 45 billion in 2022.

  • Growing Penetration of Neurological Disorders

Based on the data released by Pan American Health Organization (PAHO), in 2019, about 533,172 people died due to neurological conditions in the United States.

Challenges

  • Higher Cost Associated with the Treatment
  • Shortage of Requisite Equipment and Skilled Medical Professionals
  • Lack of Awareness in the Rural Areas

The global west syndrome market is segmented and analyzed for demand and supply by product type into solid dosage (tablet and capsule), and liquid dosage (injectable and others), out of which, the solid dosage segment is projected to witness noteworthy growth over the forecast period. The growth of the segment can be accounted to the rising consumption of medicine across the globe. For instance, in 2021, global medicine spending was estimated to be nearly USD 1 trillion.

Major Macro-Economic Indicators Impacting the Market Growth

Global-Healthcare-Expenditure

According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.

Global West Syndrome Market Regional Synopsis

Regionally, the global west syndrome market is studied into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Amongst these markets, the market in North America region is projected to hold the largest market share by the end of 2033. The growth of the market can be accounted to the escalation in the number of people living with traumatic brain injuries. For instance, in 2020, more than 60,000 people lost their lives due to traumatic brain injuries solely in the USA while approximately 150 death occurs on a daily basis in the same region.

West-Syndrome-Market

The global west syndrome market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC (Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook

Market Segmentation

Our in-depth analysis of the global west syndrome market includes the following segments:

By Product Type

  • Solid Dosage
  • Tablet
  • Capsule
  • Liquid Dosage
  • Injectable
  • Others

By Administration Route

  • Parenteral
  • Oral
  • Others

By Treatment

  • Anticonvulsant
  • Benzodiazepine
  • Corticosteroids
  • Vitamin B

By Distribution Channel

  • Retail
  • Online
  • Hospitals

By End-User

  • Hospitals
  • Homecare
  • Clinics

Top Featured Companies Dominating the Global West Syndrome Market

  • Marinus Pharmaceuticals, Inc.
    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis
  • SK Biopharmaceuticals Co., Ltd.
  • Alkem Laboratories Ltd.
  • Supernus Pharmaceuticals, Inc.
  • Eisai Co., Ltd.
  • Abbott Laboratories
  • Upsher-Smith Laboratories, LLC.
  • Pfizer Inc.
  • H. Lundbeck A/S
  • UCB S.A.

 

FREQUENTLY ASKED QUESTIONS


Related Reports


Disclaimer | Privacy Policy | Terms & Conditions | LOB

Copyright © 2022 Research Nester. All Rights Reserved